LinkedIn respects your privacy

LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads) on and off LinkedIn. Learn more in our Cookie Policy.

Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings.

POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company’s cover photo

POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company

POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company

Biotechnology

Indianapolis, Indiana 22,009 followers

Accelerating Precision Medicine™

Follow

View all 71 employees

About us

POINT Biopharma develops next-generation radioligand therapies for the treatment of cancer

Website: http://www.pointbiopharma.com
External link for POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company
Industry: Biotechnology
Company size: 51-200 employees
Headquarters: Indianapolis, Indiana
Type: Public Company
Founded: 2019
Specialties: Radioligand, Radiopharmaceutical, Cancer, and Oncology

Locations

Primary

4850 W 78th St

Indianapolis, Indiana 46268, US

Get directions

Employees at POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company

See all employees

Similar pages

Browse jobs

Funding

POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company 3 total rounds

Last Round

Post IPO equity Oct 13, 2022

US$ 125.0M

See more info on crunchbase

By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.